NCT05057273View on ClinicalTrials.gov

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 30, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Crohn's Disease

Interventions

DRUG

BT-11

Oral once daily tablet

DRUG

Active comparator

Biologic

Sponsors

Lead Sponsor

NImmune Biopharma

All Listed Sponsors

lead

NImmune Biopharma

INDUSTRY

NCT05057273 - Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease | Biotech Hunter | Biotech Hunter